12:31 PM · 13 May 2020

Gilead Sciences signed a deal for remdesivir.

Gilead Sciences (GILD.US)   announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.


Gilead Sciences (GILD.US)  shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5

13 November 2026, 6:30 PM

Three Markets to Watch Next Week (13.11.2026)

13 November 2026, 2:48 PM

US Open: Wall Street tries to recover as Nvidia and Fed uncertainty weigh on sentiment

13 November 2026, 7:59 AM

Economic Calendar: U.S. PPI inflation takes center stage. What will today's session bring❓

13 November 2026, 6:45 AM

Morning Wrap - Will the markets recover from the scandal involving Nvidia's ousted CEO❓

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits